%0 Journal Article
%T Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors
%A Alexander K. Tsai
%A Eduardo Davila
%J Archive of "Oncoimmunology".
%D 2016
%R 10.1080/2162402X.2015.1122158
%X Adoptive cell transfer (ACT) is an emerging anticancer therapy that has shown promise in various malignancies. Redirecting antigen specificity by genetically engineering T cells to stably express receptors has become an effective variant of ACT. A novel extension of this approach is to utilize engineered T cells to produce and deliver anticancer therapeutics that enhance cytotoxic T cell function and simultaneously inhibit immunosuppressive processes. Here, we review the potential of using T cells as therapeutic-secreting vehicles for immunotherapies and present theoretical and established arguments in support of further development of this unique cell-based immunotherapy
%K Adoptive transfer
%K cell vehicle
%K cancer therapy
%K drug delivery
%K genetic engineering
%K T cell
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910704/